Oct 09, 2020 / 02:00PM GMT
Rajesh Narendran -
Good morning. Good morning, and welcome. I would like to -- first like to remind everyone to please mute your line when you're not speaking. For media and press, the FDA press contact is Lindsey O'Keefe. Her e-mail and phone number are currently displayed. We'll wait for it to be displayed. There it is.
My name is Dr. Raj Narendran. I will be chairing today's meeting. I will now call the October 9, 2020, Joint Meeting of the Psychopharmacologic Drug Advisory Committee and the Drug Safety and Risk Management Advisory Committee Meeting to order. Dr. LaToya Bonner is the designated Federal Officer for today's meeting, and we'll begin with the introductions.
I will pass it on to Dr. Bonner.
LaToya Bonner -
Good morning. My name is LaToya Bonner. I am the designated Federal Officer for today's meeting.
For the record, all voting members have confirmed via e-mail that they have viewed the pre-recorded presentation for today's meeting in their entirety. I will now proceed forth with the introduction. When I call your name, please
Alkermes Plc FDA Advisory Committee Review of New Drug Application for ALKS 3831 - Conference Call Transcript
Oct 09, 2020
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers